Schrodinger Inc
SDGR19.943USD
+0.413+2.11%
Market hours （ET）Quotes delayed by 15 min
1.46BMarket Cap
LossP/E TTM
More Details of Schrodinger Inc Company
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
Company Info
Ticker SymbolSDGR
Company nameSchrodinger Inc
IPO dateFeb 06, 2020
CEODr. Ramy Farid, Ph.D.
Number of employees891
Security typeOrdinary Share
Fiscal year-endFeb 06
Address1540 Broadway
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10036
Phone15032991150
Websitehttps://www.schrodinger.com
Ticker SymbolSDGR
IPO dateFeb 06, 2020
CEODr. Ramy Farid, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.24M
+0.49%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
36.99K
-30.96%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
25.97K
+92.81%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
23.64K
+112.26%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
12.25K
+95.95%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
12.25K
+95.95%
Michael M. Lynton ,
Michael M. Lynton ,
Independent Chairman of the Board
Independent Chairman of the Board
12.25K
+95.95%
Ms. Bridget Anne Van Kralingen
Ms. Bridget Anne Van Kralingen
Independent Director
Independent Director
11.50K
+14.99%
Mannix Aklian
Mannix Aklian
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing
--
--
Mr. Gary Ginsberg, J.D.
Mr. Gary Ginsberg, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.24M
+0.49%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
36.99K
-30.96%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
25.97K
+92.81%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
23.64K
+112.26%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
12.25K
+95.95%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
12.25K
+95.95%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
On-premise software
25.42M
42.69%
Hosted software
10.87M
18.26%
Drug discovery services
10.24M
17.19%
Software maintenance
6.80M
11.41%
Contribution
3.84M
6.45%
Other
2.38M
4.00%
By RegionUSD
Name
Revenue
Proportion
United States
29.66M
49.81%
EMEA
23.08M
38.76%
APAC
6.07M
10.20%
Rest of World
731.00K
1.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
On-premise software
25.42M
42.69%
Hosted software
10.87M
18.26%
Drug discovery services
10.24M
17.19%
Software maintenance
6.80M
11.41%
Contribution
3.84M
6.45%
Other
2.38M
4.00%
Shareholding Stats
Updated: Fri, May 23
Updated: Fri, May 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.07%
Bill & Melinda Gates Foundation Trust
10.87%
The Vanguard Group, Inc.
10.17%
Rubric Capital Management LP
7.48%
Nikko Asset Management Co., Ltd.
5.68%
Other
53.73%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.07%
Bill & Melinda Gates Foundation Trust
10.87%
The Vanguard Group, Inc.
10.17%
Rubric Capital Management LP
7.48%
Nikko Asset Management Co., Ltd.
5.68%
Other
53.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
48.38%
Investment Advisor/Hedge Fund
25.00%
Hedge Fund
13.63%
Endowment Fund
10.87%
Individual Investor
2.65%
Research Firm
2.22%
Pension Fund
0.80%
Bank and Trust
0.49%
Venture Capital
0.13%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
570
67.20M
104.65%
-5.08M
2025Q1
593
67.21M
104.69%
-5.43M
2024Q4
576
64.44M
100.89%
-9.04M
2024Q3
581
67.44M
105.91%
-6.15M
2024Q2
573
64.76M
101.80%
-8.12M
2024Q1
574
63.48M
100.05%
-5.40M
2023Q4
584
62.06M
98.56%
-7.64M
2023Q3
586
63.62M
101.35%
-15.42M
2023Q2
584
64.04M
102.20%
-7.30M
2023Q1
543
57.09M
91.59%
-11.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.75M
12.07%
-354.21K
-4.37%
Mar 31, 2025
Bill & Melinda Gates Foundation Trust
6.98M
10.87%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.53M
10.17%
-72.09K
-1.09%
Mar 31, 2025
Rubric Capital Management LP
4.80M
7.48%
-200.00K
-4.00%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
3.46M
5.39%
-48.10K
-1.37%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.47M
3.85%
+919.38K
+59.31%
Mar 31, 2025
Stephens Investment Management Group, LLC
1.97M
3.07%
+362.29K
+22.53%
Mar 31, 2025
State Street Global Advisors (US)
2.21M
3.44%
-104.66K
-4.52%
Mar 31, 2025
MFS Investment Management
2.09M
3.26%
-186.23K
-8.17%
Mar 31, 2025
ARK Investment Management LLC
2.29M
3.57%
+85.76K
+3.88%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
3.78%
TrueShares Technology, AI & Deep Learning ETF
2.24%
Global X HealthTech ETF
1.25%
SPDR FactSet Innovative Technology ETF
0.97%
WisdomTree BioRevolution Fund
0.84%
Franklin Exponential Data ETF
0.81%
Invesco S&P SmallCap Health Care ETF
0.8%
Franklin Genomic Advancements ETF
0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.44%
View more
ARK Genomic Revolution ETF
Proportion3.78%
TrueShares Technology, AI & Deep Learning ETF
Proportion2.24%
Global X HealthTech ETF
Proportion1.25%
SPDR FactSet Innovative Technology ETF
Proportion0.97%
WisdomTree BioRevolution Fund
Proportion0.84%
Franklin Exponential Data ETF
Proportion0.81%
Invesco S&P SmallCap Health Care ETF
Proportion0.8%
Franklin Genomic Advancements ETF
Proportion0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.46%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.44%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
